Key points are not available for this paper at this time.
Design
Review
Attenuated CVB3 strains merit further preclinical study as myocarditis vaccines; leaves open clinical translation pending human trials.
Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: